NAD+ results and expectations
NAD injections before and after: what results are supported?
NAD injections before and after do not have a proven, predictable results timeline. Small human injection studies now exist, but they do not establish how much energy, focus or visible change a new patient should expect. The evidence includes preliminary safety findings, an uncontrolled sleep study reported in a registry and a separate IV metabolite study. These answer different questions. None provides a reliable week-by-week transformation guide for the home-injection plans sold online. Before paying, ask whether a claim concerns NAD+ itself, the route you are considering and a meaningful health outcome, rather than a blood marker or someone else's testimonial.
Compares route-specific human findings with the results and timing claims a reader may encounter when choosing an NAD+ injection plan. It is a bounded source review, not a systematic review or individual medical advice.
Human injection evidence
Preliminary findings, with important limits
Reliable results timeline
Not established for online injection plans
Before buying
Match the molecule, route and measured outcome
Swipe the evidence table sideways to read every column.
| Human evidence | Route and sample | Observation window | What it can establish |
|---|---|---|---|
| 2026 safety preprint, Trial 1 | 45 participants across nine arms; NAD+ SC: 6, IM: 4, IV: 5 | Follow-up through Day 10 | Preliminary tolerability observations, not a benefit timeline |
| 2026 unpublished sleep registry results | Subcutaneous NAD+; 20 adults; no untreated control | Six weeks of dosing observation | Exploratory sleep scores, without establishing causation |
| 2019 published IV pilot | 11 men: 8 NAD+, 3 saline | Six-hour infusion; sampling through eight hours | Blood and urine metabolism, not home-injection effectiveness |
What results can you realistically expect from NAD+ injections?
The studies reviewed here do not support a dependable prediction of improved energy, clearer thinking, younger-looking skin or longer life from a current injection subscription. Their designs and endpoints do not establish those promises. This is uncertainty about benefit, rather than proof that every reported experience is false.
Keep the question specific: which outcome matters to you, how would it be assessed and which study tested it? A broad claim such as feeling younger combines several different outcomes. Evidence about one measurement cannot settle all of them or predict an individual's response.
Are there human studies of subcutaneous or intramuscular NAD+?
Yes. An April 30, 2026 preprint reports a small randomized pilot including both routes. This report concerns safety; other outcomes are reserved for separate reporting. It describes discomfort but no treatment-related serious adverse events. ChromaDex funded the research, and several authors disclosed employment or commercial interests. It remains preliminary evidence, not proof of broad benefit.
The same paper's longer second trial tested nicotinamide riboside, or NR. NR is a different intervention and its 100-day findings cannot be assigned to NAD+. The first trial's registry still lists recruiting, with an April 2025 update, despite the later report describing completed participants. Registration describes a study; a dated results report shows what has actually been reported.
How long does it take to see results from NAD+ injections?
A reliable onset or duration of benefit has not been established by this evidence. A study's follow-up window is not a deadline by which a treatment should work. Observing participants at a particular time does not establish that a new patient will improve by then, or that any improvement will last.
Treat a provider's day-by-day or month-by-month timeline as a claim to verify. Ask which outcome, comparison group and matching route support each milestone. If the answer is a testimonial or a study of a different product, that does not supply the missing evidence. A refill schedule also tells you when you pay, not when a benefit begins.
Do NAD+ before-and-after photos prove that injections work?
A photograph cannot establish that NAD+ caused a change. It does not account for lighting, expression, weight changes, skincare, other treatments or which examples were selected. Nor does it measure energy, concentration or lifespan. The studies in the table do not validate a predictable visual transformation from a home-injection plan.
Apply the same caution to testimonials. A person's report can be sincere without showing what would have happened without the injection. Look for a defined outcome assessed consistently, the number of people studied and a suitable comparison. Ask whether unchanged results, adverse experiences and people who stopped were included, rather than only successful examples.
Does a change in blood NAD+ mean a health benefit?
A biochemical measurement and a health outcome are different findings. The 2019 IV pilot measured NAD+ and related metabolites in blood and urine over hours. It did not demonstrate improvements in memory, appearance or lifespan, and its route was intravenous rather than a subcutaneous home injection.
When shown a before-and-after laboratory result, ask what was measured and whether the evidence connects that change to the outcome being promised. A larger change in a marker does not, by itself, establish a larger benefit or a better provider. The study needs to answer the health question too.
Does the newer sleep study establish quick NAD+ results?
No. A Japanese registry reports changes in modified sleep-questionnaire scores, but the study was unblinded and had no untreated control group. Participants with different baseline symptoms were compared. The registry marks the manuscript unpublished, and registration occurred after follow-up had finished.
These details make the findings exploratory. They cannot separate an injection effect from expectations, natural fluctuation or other influences. An early assessment does not establish a promise of better sleep the next day. The useful takeaway is that human work exists and needs stronger confirmation, not that a dependable sleep treatment or results schedule has been established.
What safety questions matter alongside before-and-after results?
Product quality belongs in the decision. FDA has reported severe chills, shaking, vomiting and fatigue after injectable NAD+ products, with some people needing medical treatment. The agency connected the concern to unsuitable ingredients and reactions consistent with excessive endotoxins. These reports do not provide a reaction rate for every product or provider.
Ask the service to identify the dispensing pharmacy, exact product and who handles adverse-event questions. A positive testimonial cannot establish sterility. If an experience is unpleasant or worsening, a marketing claim that the product is working is not an adequate explanation; contact the responsible clinician for assessment.
What should you ask before paying for an NAD+ plan?
Use four questions to keep the consultation focused. First, what exact change is the plan intended to achieve, and how will the clinician assess it? Second, does the supporting human study match NAD+ and the prescribed route, or does it concern IV treatment or a precursor? The differences in the evidence table make that distinction necessary.
Third, what would count as insufficient benefit or a reason to reconsider treatment with the clinician? Fourth, what are the full payment, renewal and cancellation terms while that assessment takes place? A clear price helps you budget; it does not settle whether the treatment is worthwhile.
Take these questions to the provider without treating them as a self-directed experiment or a dosing plan. You do not need to upload health details here. If you continue comparing services, use product-specific reviews and payment terms alongside the evidence limitations, rather than assuming the cheapest plan or most dramatic testimonial predicts the best result.
For the related decisions, read the NAD+ injection side-effects guide and NAD+ injections vs IV evidence comparison.
Where can I compare current NAD+ providers?
The pages below compare public product and contract information. Some are labeled partner links. Any commission we receive does not change evidence claims or table order.
Partner link; we may earn a commission. Editorial order and findings do not change.
Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate.
Sprout Health’s NAD+ injection referral offer excludes California.
Which sources support this answer?
Sources were checked October 1, 2026. They define the product, population and evidence limits used above; they do not determine individual suitability.
- medRxiv: preliminary safety analysis of injectable NR and NAD+ pilot trials, April 30, 2026 preprint
- ClinicalTrials.gov: NCT06919328, injectable Niagen versus NAD+ trial registration
- UMIN000062909: subcutaneous NAD+ sleep study and unpublished registry results
- Frontiers: Grant et al., human NAD+ IV metabolite pilot, September 12, 2019
- FDA: ingredients used in sterile compounding and injectable NAD+ adverse-event reports
These are products marketed in the longevity category, not established lifespan-extension treatments. Compounded drugs are not FDA-approved. This publication compares public information; a clinician must assess individual suitability. How we compare.